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Background: Cancer, much like most human disease, is routinely studied by utilizing model organisms. Of these
model organisms, mice are often dominant. However, our assumptions of functional equivalence fail to consider
the opportunity for divergence conferred by ~180 Million Years (MY) of independent evolution between these
species. For a given set of human disease related genes, it is therefore important to determine if functional
equivalency has been retained between species. In this study we test the hypothesis that cancer associated genes
have different patterns of substitution akin to adaptive evolution in different mammal lineages.
Results: Our analysis of the current literature and colon cancer databases identified 22 genes exhibiting colon
cancer associated germline mutations. We identified orthologs for these 22 genes across a set of high coverage
(>6X) vertebrate genomes. Analysis of these orthologous datasets revealed significant levels of positive selection.
Evidence of lineage-specific positive selection was identified in 14 genes in both ancestral and extant lineages.
Lineage-specific positive selection was detected in the ancestral Euarchontoglires and Hominidae lineages for
STK11, in the ancestral primate lineage for CDH1, in the ancestral Murinae lineage for both SDHC and MSH6 genes
and the ancestral Muridae lineage for TSC1.
Conclusion: Identifying positive selection in the Primate, Hominidae, Muridae and Murinae lineages suggests an
ancestral functional shift in these genes between the rodent and primate lineages. Analyses such as this, combining
evolutionary theory and predictions - along with medically relevant data, can thus provide us with important clues
for modeling human diseases.
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Evolutionary medicineBackground
Mouse models are currently used to research many
human cancers including colon cancer. On a genome
wide scale, mouse protein sequences share 78.5% se-
quence identity with human counterparts [1]. With such
high levels of sequence identity it may seem reasonable
to expect that many orthologs between mouse and* Correspondence: mary.oconnell@dcu.ie
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reproduction in any medium, provided the orhuman would have conserved functions. However, in the
~180 Million Years (MY) of independent evolution [2],
it is possible that certain proteins have functionally
diverged. One example of ortholog divergence between
human and mouse is the TDP1 gene, required in Topo1-
DNA complex repair, protein sequence similarity of 81%.
A point mutation from an adenine to a guanine at pos-
ition 1478 in human TDP1 is linked with a disorder
known as SCAN1 that results in cerebellar atrophy and
peripheral neuropathy. However, this mutation in mouse
does not result in the same condition/phenotype [3].
Specific mutations in any of the following genes in
human result in disease: BCL10, PKLR and SGCA, but
the same mutations in the mouse homologs do notl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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BRCA1 is heavily implicated in breast cancer in humans,
with BRCA1+/− women having a 50% risk of developing
breast cancer, while BRCA+/− mice do not exhibit
increased susceptibility to cancer [5]. These observed
differences in phenotype could potentially be the result
of protein functional shifts in cancer-associated genes
between human and mouse. While the analysis of the
mouse lineage versus human is important from an evo-
lutionary medicine perspective to determine/predict
those specific cases where mouse may not effectively
model the human disease phenotype, the analysis of all
other lineages frames these results in the context of all
mammals. Therefore, in this study we have not only
examined the human and mouse lineages but all lineages
leading to extant species in our dataset. This allows us
to gain a greater understanding of the level of lineage-
specific functional shift that has occurred in colon can-
cer associated genes.
Positive selection is the retention and spread of advan-
tageous mutations throughout a population and has long
been considered synonymous with protein functional
shift. There are a number of driving forces for positive
selection including external mechanisms such as adapta-
tion to different ecological niches and response to dis-
ease and internal mechanisms such as co-evolution and
compensatory mutations [6], all of which are relevant to
the data and species we are analyzing. At the molecular
level, the ratio of nonsynonymous substitutions per non-
synonymous site (dN) to synonymous substitutions per
synonymous site (dS) is known as ω, and indicates the
selective pressure at work in that sequence. If ω> 1 it
signifies positive selective pressure, ω= 1 signifies neutral
evolution, while ω< 1 indicates purifying selective pres-
sure. Previous work assessed the level of positive selec-
tion present in mammal genomes and estimated 5%-9%
of genes in mammals are under positive selection under
a Bayesian framework, and thus provides us with a
reference or expected level of positive selection for our
analysis [7,8].
Here we have applied a Maximum Likelihood method
based on codon models of evolution to assess the select-
ive pressures across our dataset [9]. These methods are
far more robust than alternatives such as the sliding
window approach [10], nonetheless they do suffer from
limitations and have strict criteria in terms of dataset
size for statistical robustness [11,12]. Another feature of
sequence evolution that can negatively impact on a se-
lective pressure analysis is recombination [13]. To evalu-
ate the robustness of the Likelihood Ratio Tests (LRTs),
simulations have been performed that show that type 1
error rates can be up to 90% with relatively high rates of
recombination in protein coding sequences resulting
in the misinterpretation of recombination as positiveselection [13]. We have incorporated a test for recom-
bination for all genes in the dataset prior to the ML se-
lective pressure analysis. Recent studies using these
codon models of evoluton in an ML framework have
combined evolutionary predictions of positive selection
with biochemical verification of functional affects of
these substitutions [14-16], and thus support the link be-
tween positive selection and protein functional shift.
We have taken colon cancer as an example for our
study given the large amount of mutation and epigenetic
data available for this form of cancer [17]. Lineage-
specific positive selection in genes associated with colon
cancer is strongly suggestive of functional shift and
could have serious implications in the use of certain
lineages for modeling colon cancer.
Colorectal cancer (CRC) is the third most commonly
diagnosed cancer in males and second in females and we
have focused on this in our study [18]. CRC arises
through the accumulation of multiple genetic and epi-
genetic changes. Genetic changes consist of both som-
atic and germline (i.e. heritable) mutations. The genes in
which there are germline mutations that are highly asso-
ciated with the development of colon cancer are ana-
lyzed here (22 genes in total) and are referred to
throughout this manuscript as “colon cancer associated
genes”. Colon cancer associated genes work in conjunc-
tion with other proteins and pathways and can be
thought of as contributing to, rather than being the sin-
gle cause of colon cancer (note: these genes also have
other functions outside of their association that may
contribute to selective pressure variation in different
lineages). Epigenetic changes such as hypermethylation
of certain genes, loss of imprinting and acetylation/phos-
phorylation/methylation of particular histones are also
implicated in cancer. Detailed information on colon can-
cer epigenetics have been made available to the commu-
nity through the StatEpigen biomedical resource [17].
Other events such as loss of heterozygosity, microsatel-
lite instability and CpG island methylator phenotype can
also play an important role.
Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
is a hereditary predisposition for the development of
colorectal cancer, and accounts for 3% of all colon cancer
cases [19]. The 22 genes we have analyzed were selected
based on the presence of known germline mutations
associated with colon cancer. What follows is a brief de-
scription of each gene in the study. The genes linked
with HNPCC are: MLH1, PMS2, MSH2, MSH6, and
PMS1, all of which are members of the MMR DNA re-
pair pathway [19].
MLH1 (mutL homologue 1) is a mismatch repair gene
and is commonly associated with HNPCC. Missense
mutations in MLH1 occur in the C-terminal domain,
which is responsible for constitutive dimerization with
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have also shown that microsatellite instability (MSI) is
the molecular fingerprint of a deficient mismatch repair
system. It is estimated that some 15% of colorectal can-
cers display MSI owing to the epigenetic silencing of
MLH1, and/or germline mutation in any one of the fol-
lowing mismatch repair genes: PMS2, MLH1, MSH2,
and MSH6 [21]. The mismatch repair endonuclease
PMS2 is known to interact with MLH1 and is a compo-
nent of the post-replicative DNA mismatch repair sys-
tem (MMR). PMS2 is recruited to cleave damaged DNA
this recruitment is triggered by the binding of MSH2
and MSH6 proteins to dsDNA mismatches followed by
the recruitment of MLH1 (Figure 1). PMS1 is also
involved in the repair of DNA mismatches, and it can
form heterodimers with MLH1. Additional genes in our
study include the tumor suppressor gene TP53, CDH1,Figure 1 Phylogeny of animal species used in this study. The ancestra
names as used throughout the text. Those lineages where positive selectio
selection is denoted with an empty circle.MUTYH, and APC. TP53 is a hub protein in the cellular
DNA damage response pathway known as the P53 sig-
naling pathway [22], it is linked with colorectal cancer
and many other cancers. The genes CDH1, MUTYH,
and APC also interact with one another in addition to
their involvement in the MMR pathway described above.
For example, CDH1 and APC combine to act as a ubi-
quitin ligase, which is involved in glycolysis regulation
during the cell cycle [23]. In fact, most of the colon can-
cer associated genes in this study can be grouped into
critical pathways, such as apoptosis, DNA damage con-
trol, and cell cycle signaling [24].
To assess if there is evidence for protein functional
shift from the patterns of substitution in colon cancer
associated genes we have carried out selective pressure
analyses using codon models of lineage-specific rate
heterogeneity.l lineages tested in the analysis are labeled with their corresponding
n was detected are labeled with filled circles, no evidence of positive
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Sequence data assembled
The colon cancer gene dataset used in this study con-
sists of 22 genes taken from the Cancer Gene Census at
the Sanger Institute [25]. All 22 genes have reported
cases of germline mutations that are associated with
colon cancer (See Table 1 for summary of data, detail on
the complete dataset is available in Additional file 1).
Using Compara data from Ensembl [26,27], single gene
orthologs were identified for each gene across the verte-
brate genomes chosen. The 21 species were selected
based on genome coverage. These included representa-
tives from 3 of the 4 main lineages of Eutheria, namely
Afrotheria, Euarchontoglires, and Laurasiatheria, as well
as outgroup species including platypus, zebrafish, and
zebra finch (see Additional file 1).
Multiple sequence alignment
The coding DNA sequences of the single gene orthologs
were translated and the resulting amino acid sequences
were aligned using the default parameters in ClustalW
2.0.12 [30,31]. We mapped gaps from the amino acid
multiple sequence alignment (MSA) to the corre-
sponding nucleotide sequences to produce a nucleo-
tide alignment. All alignments were reviewed for
quality and any poorly aligned regions were manually
edited using Se-Al [32]. All alignments are available
in Additional file 2.
Alignment criteria for selective pressure analysis
It has been shown through computer simulations that
sequence length has an impact on the power to infer
positive selection [33]. Power was also found to increase
with greater taxonomic representation and greater diver-
gence, although extreme levels of divergence were found
to cause a reduction in power. Simulations have shown
that the presence of longer foreground branches also
increased the power of the test statistic, but extremely
long foreground branches reduced the power [34]. To
increase the statistical power of the analyses performed
here we have therefore only considered single gene fam-
ilies containing 6 or more taxa, and alignment lengths of
greater than 500 amino acids.
Recombination analysis
Recombination events can result in the incorrect detec-
tion of positive selection. To reduce the detection of po-
tential false positives from our analyses, we have
implemented GENECONV (version 1.81a) [35]. GENE-
CONV detects gene conversion events between ances-
tors of sequences in a multiple sequence alignment.
Default parameters where employed, and 10,000 ran-
domly permuted datasets were generated for each SingleGene Orthologous family and global inner fragments
were listed if P-value <= 0.05 or smaller.
Selective pressure analysis using codon models of
evolution
Selective pressure analyses were performed using
Codeml from PAML version 4.4 [36,37]. Because each
gene family analyzed was composed of single gene
orthologs, pruned species phylogenies were used as per
previous publications [2,38]. Codeml implements a num-
ber of codon-based models in a Maximum Likelihood
framework that can be used to test alternative and
nested evolutionary hypotheses. Three different types of
codon model were used in this study: (i) a homogeneous
model (Model 0) - a single ω-value is estimated for the
entire alignment; (ii) site-heterogeneous models - the
sites of the gene sequence are grouped into two or more
site classes, each with its own ω-value; and (iii) lineage-
specific heterogeneous models - a different ω parameter
is estimated for different site classes in combination with
different lineages [9,36,39].
Seven site-heterogeneous models were used, we have
retained conventional annotations for these models:
Model 1a (Nearly Neutral), Model 2a (Selection), Model
3 Discrete (k = 2), Model 3 Discrete (k = 3), Model 7,
Model 8 and Model 8a. Two lineage-specific heteroge-
neous models were used: Model A and Model A Null.
These models have been applied similarly elsewhere [40].
The goodness-of-fit of the different models was
assessed statistically using a likelihood ratio test (LRT).
The LRT compares the log-likelihoods of a null model
with the alternative model. For hierarchically nested
models, the test statistic of an LRT approximates the χ2
distribution with degrees of freedom equal to the num-
ber of additional free parameters in the alternative
model compared to the null model. Because of this, the
critical value of the test statistic can be determined from
standard statistical tables. If the p-value of the test statis-
tic exceeds that critical value (i.e. if the alternative model
fits the data significantly better than the null model),
then the null model can be rejected. For example, if the
test statistic of an LRT comparing Model 1a (Nearly
Neutral) with Model 2a (Selection) is greater than the
critical value determined from the χ2 distribution, Model
1 a can be rejected. If ω1> 1 under Model 2a, positive
selection may be inferred. Additional file 3 shows the set
of LRTs used for selective pressure analysis.
In cases where positive selection is inferred, the pos-
terior probability of a site belonging to the positively
selected class is estimated using two calculations: Naïve
Empirical Bayes (NEB) or Bayes Empirical Bayes (BEB).
If both BEB and NEB are predicted, we will preferen-
tially use the BEB results as these have been shown to be
more robust [37].
Table 1 Colon Cancer Gene Set analyzed in this study
Gene
(HGNC
code)
Ensembl
Identifier
Taxa
Number2
Alignment
Length3
Syndrome Tumor Types
Observed
Pathway(s) References4
APC ENSG00000134982 20 9177 Familial adenomatous
polyposis (FAP)
Colon, thyroid,
stomach, intestine
APC [19,24]
ATM ENSG00000149311 18 9189 Ataxia telangiectasia (A-T) Leukemia, lymphoma,
colorectal
CIN [24],
[17]
BHD ENSG00000154803 20 1737 Birt-Hogg-Dube syndrome Renal, colon AMPK, mTOR,
STAT
[24]
BMPR1A ENSG00000107779 19 1596 Juvenile polyposis Gastrointestinal SMAD [24]
CDH1 ENSG00000039068 15 2649 Familial gastric carcinoma Stomach AP [[24,28]
(E-cadherin)]
MADH4 ENSG00000141646 16 1656 Juvenile polyposis Gastrointestinal SMAD [[24], (SMAD4)]
MET ENSG00000105976 21 4146 Hereditary papillary
renal cell carcinoma (HPRCC)
Kidney, colorectal RAS, PI3K, STAT,
Beta-catenin, Notch
[24]
MLH1 ENSG00000076242 19 2274 Hereditary non-polyposis
colon cancer (HNPCC)
Colon, uterus MMR [24]
MSH2 ENSG00000095002 18 2802 Hereditary non-polyposis
colon cancer (HNPCC)
Colon, uterus MMR [24]
MSH6 ENSG00000116062 19 4101 Hereditary non-polyposis
colon cancer (HNPCC)
Colon, uterus MMR [24]
MUTYH ENSG00000132781 21 1569 Attenuated Polyposis Colon BER [24]
NF1 ENSG00000196712 17 8523 Neurofibromatosis type I Neurofibroma,
colon
RTK [24]
PMS1 ENSG00000064933 20 2799 Hereditary non-polyposis
colon cancer (HNPCC)
Colon, uterus MMR
PMS2 ENSG00000122512 21 2592 Hereditary non-polyposis
colon cancer (HNPCC)
Colon, uterus MMR [24]
PTEN ENSG00000171862 18 1209 Cowden syndrome Hamartoma, glioma,
colorectum
PI3K [24],
[17]
SDHB ENSG00000117118 18 840 Hereditary paraganglioma,
Carney–Stratakis
Paragangliomas,
pheochromocytomas,
gastrointestinal
HIF1 [24]
SDHC ENSG00000143252 16 507 Hereditary
paraganglioma,
Carney–Stratakis
Paragangliomas,
pheochromocytomas,
gastrointestinal
HIF1 [24]
STK11 ENSG00000118046 18 1320 Peutz-Jeghers
syndrome
Intestinal, ovarian,
pancreatic, colorectal
PI3K [24,29]
TP53 ENSG00000141510 16 1185 Li-Fraumeni
syndrome/sarcoma
Breast, sarcoma,
adrenal, brain,
colorectal
p53 [24,29]
TSC1 ENSG00000165699 18 3495 Tuberous sclerosis Hamartoma, kidney,
colorectal
PI3K [24,29]
TSC2 ENSG00000103197 19 5436 Tuberous sclerosis Hamartoma, kidney,
colorectal
PI3K [24,29]
VHL ENSG00000134086 18 639 Von Hippel-Lindau syndrom Kidney, colorectal HIF1 [24]
Each of the 22 genes analyzed in this study are detailed, including their HGNC approved gene symbols, and Ensembl gene IDs. The total number of species
analyzed for each gene and the overall length of alignment in base pairs are also given. The syndrome, tumor type observed and pathway involved are detailed.
References citing alternative gene names are identified using rounded parentheses.
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for analysis and to process all output. PAML output
files were parsed for parameter estimates and log like-
lihood values, and LRTs were performed (seeAdditional file 3). Where positively selected sites were
inferred under a given model, positively selected sites
were mapped to the sequence (or sequences) of inter-
est and included in the summary file (see Additional
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for human error in setting up and interpreting PAML
analyses and is available from the authors on request.
Functional annotation of sites under positive selection
for each protein was obtained from UniProt [41].
Human population analysis
Selective pressures within the present day human popu-
lation were analyzed for those genes with evidence of
lineage-specific positive selection in the human ancestral
lineages. The online tool SNP@Evolution2 and HapMap
release II source data was used to look at variations
within the East Asian (A), Northern and Western Euro-
pean (C), and African Yoruba (Y) populations. The
“integrated haplotype score” or iHS, described first in
[42], was employed here as a test for directional selec-
tion. The iHS is standardized using genome wide empir-
ical distributions, it has an approximate normal
distribution allowing for direct comparisons of the score
across genes, and it outperforms in comparison to other
available approaches [42]. A derived allele that has been
segregating in the population receives a large iHS (>+ 2)
while a large negative iHS (<−2) indicates that the
derived allele has increased in frequency.
Results and discussion
Starting with a dataset of 22 genes, we identified single
gene orthologs across 21 complete vertebrate genomes.
Ortholog identification resulted in families with between
15 and 21 taxa, and alignment lengths of between 507
and 9,189 base pairs thus satisfying the criteria
described in the materials and methods section. The test
for recombination on all 22 genes is summarized in
Additional file 5. The analysis revealed that only the
TP53 protein showed significant levels of recombination,
the regions where recombination was present were
noted and compared to regions where positive selection
was detected. If these regions overlapped - the positive
selection result was deemed a false positive.
To assess the selective pressure variation, we per-
formed both site- and lineage-specific selective pres-
sure analyses and subsequently assessed the statistical
significance of all results via LRT analyses to ascertain
the codon evolutionary model of best fit. In those
cases where the ω value vastly exceeds 1, we have
simply denoted them as ω >> 1 throughout the
manuscript, as there is no biological significance for
these extremely large ω values (the precise numbers
are shown in the Tables throughout). The lineage-
specific analyses are more pertinent to the main focus
of the paper, i.e. - the identification of species-specific
patterns of substitution in these colon cancer asso-
ciated genes. Therefore the lineage-specific results
have been described in detail in the following section.Site-specific results are briefly summarized on a gene-
by-gene basis. All positively selected sites were
assessed using functional information from the Uni-
prot database [41]. The model of best fit along with
associated parameter estimates are described and a
summary table for each of the 22 genes is given in
Additional file 4.
Lineage-specific selective pressure analyses
Lineage-specific models of codon evolution were
assessed at multiple phylogenetic depths, (i) the ex-
tant lineages within the Euarchontoglires clade, and
(ii), all ancestral lineages leading from the Euarchon-
toglires to modern mouse and human were also
tested independently as depicted in Figure 1. Analysis
of the extant human and mouse lineages did not yield
evidence of positive selection. Conversely, analysis of
the lineages within the Euarchontoglires clade resulted
in significant evidence of lineage-specific positive se-
lection, 6 genes in ancestral lineages and 12 in extant
lineages, see Figure 1. The STK11 gene showed evi-
dence of positive selection in the Euarchontoglires an-
cestral lineage and again in the Hominidae ancestral
lineage. CDH1 showed patterns of substitution condu-
cive with positive selection in the ancestral primate
lineage. In the ancestral Muridae lineage there is evi-
dence for positive selection acting on the TSC1 gene.
The ancestral Murinae lineage showed evidence of
positive selection for both MSH6 and SDHC, see
Table 2 for summary.
In the following section, we have analyzed the posi-
tively selected sites for those genes with evidence of
lineage-specific positive selection in the context of
their potential functional relevance for those genes.
This was carried out for all genes where functional
sites and/or domains have been elucidated. All sites
described were calculated via Bayes Empirical Bayes
(BEB) analysis (unless otherwise specified). In all cases
we are assessing the potential functional importance
of residues based on their sequence position. There
are instances where we identify stretches of protein
sequence under positive selection - there is a possibil-
ity that these sites may have very different functions
despite their sequence position. For a total 16 of the
22 genes there were partial or complete 3D structures
available. However, many of the positively selected
sites identified were located in regions that were not
yet fully resolved at the structural level, and so only
the 3D model for STK11 is given.
Positive selection in the Euarchontoglires Ancestral branch
The most ancestral branch tested was the Euarchon-
toglires ancestral branch, i.e. the ancestor of the Pri-
mate, Rodent and Glires clades as depicted in
Table 2 Summary of parameter estimates and likelihood scores for the model of best fit showing evidence of positive
selection
Gene Model lnL Parameter Estimates Positive
Selection
BEB Positively Selected
Sites
Lineage-Specific Analyses
Euarchontoglires Ancestral Branch
STK11 modelA −8602.921472 p0 = 0.93299, p1 = 0.05633, p2 = 0.01007, p3 = 0.00061
ω0 = 0.03346, ω1 = 1.00000, ω2 = 197.90897
Yes 3> 0.50, 1> 0.95, 0> 0.99
Primate Ancestral Branch
CDH1 modelA −16658.03484 p0 = 0.75454, p1 = 0.23453, p2 = 0.00834, p3 = 0.00259
ω0 = 0.05683, ω1 = 1.00000, ω2 = 10.20516
Yes 9> 0.50, 1> 0.95, 0> 0.99
Hominidae Ancestral Branch
STK11 modelA −8601.056009 p0 = 0.93574, p1 = 0.05920, p2 = 0.00476, p3 = 0.00030
ω0 = 0.03323, ω1 = 1.00000, ω2 = 44.31709
Yes 3> 0.50, 2> 0.95, 1> 0.99
VHL modelA −4263.853291 p0 = 0.73748, p1 = 0.25109, p2 = 0.00853, p3 = 0.00290
ω0 = 0.05985, ω1 = 1.00000, ω2 = 220.34533
Yes 1> 0.50, 0> 0.95, 0> 0.99
Chimpanzee Extant Branch
TSC2 modelA −42659.27711 p0 = 0.90352, p1 = 0.09434, p2 = 0.00194, p3 = 0.00020
ω0 = 0.04404, ω1 = 1.00000, ω2 = 190.09480
Yes 6> 0.50, 2> 0.95, 2> 0.99
VHL modelA −4262.098043 p0 = 0.73571, p1 = 0.25251, p2 = 0.00877, p3 = 0.00301
ω0 = 0.05976, ω1 = 1.00000, ω2 = 262.72662
Yes 3> 0.50, 0> 0.95, 0> 0.99
Gorilla Extant Branch
MSH2 modelA −19485.4338 p0 = 0.92233, p1 = 0.06298, p2 = 0.01375, p3 = 0.00094
ω0 = 0.06427, ω1 = 1.00000, ω2 = 999.00000
Yes 46> 0.50, 34> 0.95, 18> 0.99
TSC2 modelA −42569.22884 p0 = 0.89862, p1 = 0.08796, p2 = 0.01222, p3 = 0.00120
ω0 = 0.04339, ω1 = 1.00000, ω2 = 999.00000
Yes 27> 0.50, 14> 0.95, 12> 0.99
MSH6 modelA −34009.90221 p0 = 0.78382, p1 = 0.18418, p2 = 0.02591, p3 = 0.00609
ω0 = 0.06974, ω1 = 1.00000, ω2 = 999.00000
Yes 46> 0.50, 34> 0.95, 18> 0.99
ATM modelA −69374.08393 p0 = 0.80673, p1 = 0.17971, p2 = 0.01109, p3 = 0.00247
ω0 = 0.09745, ω1 = 1.00000, ω2 = 999.00000
Yes 48> 0.50, 23> 0.95, 19> 0.99
Orangutan Extant Branch
TSC1 modelA −24068.71106 p0 = 0.79963, p1 = 0.18828, p2 = 0.00978, p3 = 0.00230
ω0 = 0.08020, ω1 = 1.00000, ω2 = 999.00000
Yes 13> 0.50, 6> 0.95,5> 0.99
TSC2 modelA −42673.92339 p0 = 0.90414, p1 = 0.09295, p2 = 0.00263, p3 = 0.00027
ω0 = 0.04433, ω1 = 1.00000, ω2 = 40.47366
Yes 9> 0.50, 0> 0.95, 0> 0.99
Marmoset Extant Branch
TSC2 modelA −42616.04524 p0 = 0.89841, p1 = 0.09019, p2 = 0.01035, p3 = 0.00104
ω0 = 0.04325, ω1 = 1.00000, ω2 = 235.10448
Yes 38> 0.50, 9> 0.95
MSH6 modelA −34009.90221 p0 = 0.78382, p1 = 0.18418, p2 = 0.02591, p3 = 0.00609
ω0 = 0.06974, ω1 = 1.00000, ω2 = 999.00000
Yes 45> 0.50, 16> 0.95, 12> 0.99
VHL modelA −4262.443441 p0 = 0.72045, p1 = 0.22453, p2 = 0.04195, p3 = 0.01307
ω0 = 0.05886, ω1 = 1.00000, ω2 = 90.26952
Yes 10> 0.50, 0> 0.95, 0> 0.99
ATM modelA −69583.23068 p0 = 0.81640, p1 = 0.18148, p2 = 0.00173, p3 = 0.00038
ω0 = 0.09939, ω1 = 1.00000, ω2 = 46.82466
Yes 2> 0.50, 0> 0.95, 0> 0.99
Muridae Ancestral Branch
TSC1 modelA −24126.17894 p0 = 0.80995, p1 = 0.18416, p2 = 0.00481, p3 = 0.00109
ω0 = 0.08293, ω1 = 1.00000, ω2 = 999.00000
Yes 1> 0.59, 0> 0.95, 0> 0.99
Murinae Ancestral Branch
SDHC modelA −3846.690164 p0 = 0.87666, p1 = 0.08131, p2 = 0.03846, p3 = 0.00357
ω0 = 0.15340, ω1 = 1.00000, ω2 = 253.61375
Yes 9> 0.50, 2> 0.95, 1> 0.99
MSH6 modelA −34190.13821 p0 = 0.79911, p1 = 0.19671, p2 = 0.00335, p3 = 0.00082
ω0 = 0.07057, ω1 = 1.00000, ω2 = 126.22513
Yes 3> 0.50, 1> 0.95, 0> 0.99
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Table 2 Summary of parameter estimates and likelihood scores for the model of best fit showing evidence of positive
selection (Continued)
Rat Extant Branch
MADH4 modelA −6092.186945 p0 = 0.93360, p1 = 0.01536, p2 = 0.05021, p3 = 0.00083
ω0 = 0.01379, ω1 = 1.00000, ω2 = 102.33013
Yes 24> 0.50, 11> 0.95, 10> 0.99
NF1 modelA −37750.29866 p0 = 0.96609, p1 = 0.02476, p2 = 0.00892, p3 = 0.00023
ω0 = 0.02265, ω1 = 1.00000, ω2 = 999.00000
Yes 39> 0.50, 10> 0.95, 10> 0.99
Guinea pig Extant Branch
TSC1 modelA −24116.58577 p0 = 0.80206, p1 = 0.18611, p2 = 0.00961, p3 = 0.00223
ω0 = 0.08093, ω1 = 1.00000, ω2 = 284.22603
Yes 9> 0.50, 4> 0.95, 0> 0.99
NF1 modelA −37849.50819 p0 = 0.97375, p1 = 0.02506, p2 = 0.00116, p3 = 0.00003
ω0 = 0.02414, ω1 = 1.00000, ω2 = 171.64068
Yes 3> 0.50, 1> 0.95, 0> 0.99
Rabbit Extant Branch
MLH1 modelA −19516.63525 p0 = 0.80595, p1 = 0.18541, p2 = 0.00703, p3 = 0.00162
ω0 = 0.05262, ω1 = 1.00000, ω2 = 7.52747
Yes 5> 0.05, 3> 0.95, 0> 0.99
MUTYH modelA −15911.6175 p0 = 0.61027, p1 = 0.37605, p2 = 0.00846, p3 = 0.00522
ω0 = 0.07703, ω1 = 1.00000, ω2 = 998.99697
Yes 5> 0.50, 4> 0.95, 3> 0.99
SDHC modelA −3822.683246 p0 = 0.57771, p1 = 0.06636, p2 = 0.31926, p3 = 0.03667
ω0 = 0.12047, ω1 = 1.00000, ω2 = 3.59059
Yes 51> 0.50, 10> 0.95, 8> 0.99
ATM modelA −69582.95152 p0 = 0.81572, p1 = 0.18045, p2 = 0.00313, p3 = 0.00069
ω0 = 0.09930, ω1 = 1.00000, ω2 = 7.41594
Yes 6> 0.50, 0> 0.95, 0> 0.99
BHD modelA −13523.51719 p0 = 0.90728, p1 = 0.05930, p2 = 0.03137, p3 = 0.00205
ω0 = 0.02817, ω1 = 1.00000, ω2 = 6.50017
Yes 10> 0.50, 7> 0.95, 1> 0.99
Site-specific Analyses
CDH1 m8 −16589.88768 p = 0.21848, p0 = 0.99291, p1 = 0.00709,
q = 0.80842 ω=4.53766
Yes 15> 0.5, 1> 0.95, 0> 0.99
PMS1 m8 −26480.39761 p = 0.61337, p0 = 0.93580, p1 = 0.06420,
q = 1.93110 ω=1.32691
Yes 25> 0.50, 1> 0.95, 0> 0.99
PMS2 m8 −27449.3651 p = 0.29104, p0 = 0.91064, p1 = 0.08936,
q = 1.31619 ω=1.28855
Yes 37> 0.50, 1> 0.95, 0> 0.99
MUTYH m8 −15797.6226 p = 0.37255, p0 = 0.97242, p1 = 0.02758,
q = 1.00900 ω=2.44412
Yes 18> 0.5, 1> 0.95, 0> 0.99
TP53 m8 −8688.19126 p = 0.40362, p0 = 0.94645, p1 = 0.05355,
q = 1.77507 ω=1.97385
Yes 13> 0.5, 3> 0.95, 0> 0.99
The model of best fit is summarized below for those genes with evidence of positive selection. The lineage-specific results for each lineage tested from the
Euarchontoglires ancestor to modern lineages are shown in the top panel and the site-specific results are shown in the bottom panel. The model abbreviations
are as per main text. P refers to the number of free parameters estimated in that model. BEB = Bayes Empirical Bayes estimations. The number of positively
selected sites identified can be found the final column, sites are separated by the posterior probability cutoffs of 0.50, 0.95, and 0.99.
Morgan et al. BMC Evolutionary Biology 2012, 12:114 Page 8 of 16
http://www.biomedcentral.com/1471-2148/12/114Figure 1. The STK11 alignment consists of 18 taxa
and was the only gene that showed evidence of posi-
tive selection in this ancestral lineage. STK11 (Serine/
Threonine-protein kinase 11) plays an essential role
in G1 cell cycle arrest and acts as a tumor suppres-
sor. It phosphorylates and activates members of the
AMPK-related subfamily of protein kinases [43,44],).
Mutations in STK11 cause Peutz-Jeghers syndrome
(PJS), this is a rare autosomal dominant disorder
characterized by multiple gastrointestinal hamartoma-
tous polyps and an increased risk of various neo-
plasms including gastrointestinal cancer [45,46]. From
the literature we currently know of 17 sites across
this gene that when mutated are associated with
colon-cancer. The Euarchontoglires ancestral lineage has1.1% of sites under positive selection (ω >> 1).
The positively selected residues were located on the 3D
structure of this enzyme (See Figure 1 inset). Position
206 with a Posterior Probability (PP) = 0.889 is a hydro-
phobic Alanine or Valine in Euarchontoglires species and
is a negatively charged Glutamic acid or positively
charged Lysine in non-Euarchontoglires species. This
residue also lies in close proximity to sporadic cancer site
A205T and colorectal cancer site D208N in Human [47].
Positively selected position 301 in Euarchontoglires
(P = 0.885) is present in Euarchontoglires species as an
Arginine residue and all non-Euarchontoglires as an
uncharged Glutamine residue. Site 301 is close to
R297K and region 303–306 both of which have been
implicated in PJS [48].
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The branch leading from the Euarchontoglires ancestor
towards the primates was analyzed, we have termed
this branch the ancestral Primate branch as depicted in
Figure 1. The CDH1 dataset consists of 15 taxa and fol-
lowing LRT analyses showed evidence of lineage-specific
positive selection in 1.1% of sites in the Primate Ances-
tor (ω=10.21). Positively selected sites were compared to
human Swiss-Prot entry (P12830) and it was found that
position 604, with a PP of 0.549, falls in close proximity
to gastric cancer variant R598Q [49]. At position 604
Primates have a negatively charged Glutamic acid while
non-primates have a polar uncharged Glutamine.
Positive selection in the Hominidae Ancestral branch
The next branch in the primate clade is that leading
to modern great apes, i.e. Hominidae, as depicted in
Figure 1. This lineage also showed evidence of posi-
tive selection again in the STK11 gene in 0.51% of
sites, with ω >> 1. See Figure 2(a) and Table 2. The
positively selected positions were compared to the
human Swiss-Prot sequence (Q15831). Position 347
represents a radical substitution, as the Hominidae codeFigure 2 Positive selection analysis for 4 genes: (a) STK11, (b) CDH1,
end of alignment. The Y-axis is the posterior probability. The vertical red ba
from human populations. The black dots on each graph represent the posfor an Alanine (a small hydrophobic residue) whereas
the Murinae lineage encode an Arginine at this position
(a basic, hydrophilic, and positively charged residue).
For positively selected site 378, the ancestral Hominidae
lineage encodes the polar residue Serine, while the
closely related species studied encode the small amphi-
philic Glycine. The functions of these specific sites have
not been reported thus far in the literature but are likely
to be of considerable interest as they mark adaptations
unique to the ancestral Hominidae.
A second gene showing evidence of positive selec-
tion in the Hominidae ancestral branch is the VHL
dataset consisting of 18 taxa. The VHL gene encodes
Von Hippel-Lindaue tumour suppressor protein.
Mutations occurring in this gene can result in von
Hippel-Lindau disease (VHDL) - a dominantly inher-
ited familial cancer syndrome [50]. VHL exhibited
weak evidence of positive selection with 1.1% of sites
in the ancestral Hominidae lineage under positive se-
lection. There was one amino acid that had low
coverage in the alignment (present only in 6/18 spe-
cies), as this is a very weak results we have not
expanded upon it any further.(c) MUTYH, and (d) TP53. The x-axis depicts the gene from start to
rs on each graph represent the known cancer causing variants
itively selected sites identified in this study.
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Analysis of modern non-human primates also identified
positive selection in a number of genes. In VHL positive
selection was detected in the Chimpanzee lineage where
1.2% of sites have ω >> 1, and also in the Marmoset
lineage where 5.5% sites have ω >> 1. Sites under posi-
tive selection were compared against human Swiss-Prot
entry (P40337), however the region (1–60) was only
represented by 11/18 species in the alignment and there-
fore we do not have sufficient confidence in these posi-
tions to explore these sites in more detail.
The MSH6 gene dataset contained 19 taxa and showed
evidence of positive selection in both the Gorilla and
Marmoset lineages each displaying 3.2% of sites with
ω >> 1. Gorilla and Marmoset extant lineages were
compared against human (P52701) Swiss-Prot entry. No
relevant functional information could be extracted from
positively selected sites in Gorilla, however 2/45 posi-
tively selected sites in Marmoset fall in close proximity
to cancer variants. In marmoset, positively selected site
803 (PP = 0.551) coincides with Human colorectal cancer
variants D803G [51] and V800A [52]. Position 803 in
Marmoset is a negatively charged Glutamic acid while in
all other mammals it is a small negatively charged
Aspartic acid. Positively selected site 1099 in Marmoset
(PP = 0.614) is located between human colorectal cancer
variants R1095H [53] and T1110C [54].
MSH2 alignment consists of 18 taxa. The function of
the MSH2 protein is in post-replicative DNA mismatch
repair system (MMR). Mutations in MSH2 result in
hereditary non-polyposis colorectal cancer type 1
(HNPCC1) [55]. Lineage-specific positive selection was
identified in 1.5% of sites within the extant Gorilla
lineage with ω >> 1. Positively selected sites were com-
pared against human Swiss-Prot sequence (P43246). All
15 of the BEB identified sites occur between amino acid
position 124–142 which overlaps with the region con-
taining variants N127S, N139S and I145M associated
with HNPCC1 [55].
Tuberous sclerosis 2 protein (TSC2) interacts with
TSC1 protein and mutations in this gene can cause tu-
berous sclerosis type 2 [56]. The alignment of TSC2
consisted of 19 taxa. Lineage-specific positive selection
was identified in the following extant lineages, the per-
centage of sites under positive selection in each lineage
is shown in brackets, in all cases ω >> 1: Chimpanzee
lineage (0.2%), Gorilla (1.3%), Orangutan (0.29%), and,
Marmoset (1.1%). Positively selected sites were com-
pared against human Swiss-Prot sequence (P49815)
however the functional information was not available to
contextualize these results.
ATM acts as a DNA checkpoint sensor by activating
checkpoint signaling upon double strand breaks [57].
The alignment of ATM consisted of 18 taxa and positiveselection was detected in the following lineages (again
the percentage of the alignment under positive selection
is shown in brackets): Gorilla (1.4%, ω >> 1), Marmoset
(0.21%, ω >> 1), and Rabbit (0.38%, ω = 7.42). BEB sig-
nificant sites were compared to human (Q13315) and
mouse (Q62388) Swiss-Prot entries to determine the
functional relevance of selected sites. In the Gorilla
lineage positively selected site 2067 (PP = 0.787), where
in humans a substitution of Alanine to Aspartate in this
same position can result in Ataxia telangiectasia (AT)
which is a severe disease that causes weakened immune
function and greater predisposition to cancer [57]. No
other functionally relevant information was found upon
comparison of Swiss-Prot information against either
Marmoset or Rabbit.
The extant Orangutan lineage also showed evidence of
positive selection in the TSC1 gene for 1.2% of its align-
ment (ω >> 1). Positively selected sites were compared
against human Swiss-Prot sequence (Q92574) and
mouse Swiss-Prot sequence (Q9EP53) however there
was insufficient information to extrapolate the potential
functional impact of these sites.
Human population level analysis using HapMap data
Genes displaying evidence of positive selection in
lineages leading to Homo sapiens, i.e. the primate and
Hominidae lineages (STK11, CDH1 and VHL), were fur-
ther analyzed to determine if there is evidence for on-
going positive directional selection in modern day
human populations. The integrated haplotype score, iHS
[42], was calculated for each SNP in STK11, CDH1 and
VHL genes across African Yorubu (Y), East Asian (A)
and European (C) populations. One intronic SNP in the
SDK11 gene, had an iHS score of +2.0385 in European
populations. In the CDH1 gene, two intronic SNPs with
iHS scores of +2.0433 and +2.5838 respectively were
identified in the East Asian populations. iHS scores of
greater than +2 indicate that these alleles are segregating
at a significant rate within their given populations. No
population level directional selection was identified in
the VHL gene in modern humans.
Positive selection in the Ancestral Muridae branch
The ancestral Muridae branch marks the most recent
common ancestor of modern mouse, rat and guinea pig
species and is depicted in Figure 1. Tuberous sclerosis 1
protein (TSC1) interacts with TSC2 and acts as a
tumour suppressor gene [56]. Defects in TSC1 cause tu-
berous sclerosis type 1 which is an autosomal dominant
multi-system disorder. There were a total of 18 taxa ana-
lysed in for the TSC1 gene and 0.59% of sites in the
Muridae ancestral lineage were identified with ω >> 1.
As before for TSC1: positively selected sites were com-
pared against human Swiss-Prot sequence (Q92574) and
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was insufficient information to extrapolate potential
functional impacts of these sites.
Positive selection in the Ancestral Murinae branch
The ancestral Murinae branch defines the most recent
common ancestor of mouse and rat. In total there were
two genes identified as being under positive selection in
the Murinae lineage. The first is the MSH6 gene that
acts as a DNA mismatch repair protein and is a compo-
nent of the post–replicative DNA mismatch repair sys-
tem [58]. MSH6 also heterodimerizes with MSH2 to
form MutS-alpha, a protein complex that functions by
binding to DNA mismatches and initiating DNA repair
[59]. Mutations in MSH6 have been reported to cause
HNPCC type 5 [60], atypical HNPCC, and familial colo-
rectal cancers (suspected or incomplete HNPCC) [61].
The MSH6 dataset consists of 19 taxa. Lineage-specific
analysis of the ancestral Murinae lineage revealed 0.42%
of the sites (3 residues) in MSH6 under positive selec-
tion, ω >> 1 (see Table 2). The corresponding Swiss-
Prot sequence (P54276) lacked functional details for
these positions, therefore, potential functional effects re-
main unknown. However, examination of the alignment
at this position revealed the substitution of residues with
unrelated biochemical properties at these positions. At
positively selected site 374 (numbered as per Swiss-Prot
entry), the Murinae lineage has a Proline whereas
remaining species tested encode either Glutamic acid,
Aspartic acid, or Lysine. As Proline produces “kinks” in
the α-helical regions of proteins, such a substitution
could alter the protein structure substantially. Positively
selected site 759 is a Leucine in the Murinae, all other
non-outgroup species encode aliphatic residues (Isoleu-
cine or Valine). The ancestral Murinae has a Cysteine at
Swiss-Prot position 1259 while all other species have an
Alanine at this position. These residues are of specific
interest for further in vitro functional assaying given
their uniqueness to the rodent clade and their retention
in all modern rodents tested.
The second gene with evidence of positive selection on
the ancestral Murinae lineage is the SDHC (Succinate de-
hydrogenase cytochrome b 560 subunit, mitochondrial)
gene. The SDHC function is to act as a membrane-
anchoring subunit for the SDH protein. Defects in this
protein are reported in paragangliomas and gastric stro-
mal sarcomas [62]. The dataset for the SDHC consists of
16 taxa. Lineage-specific positive selection was detected
in the ancestral Murinae lineage with 4.2% of sites (9
residues) in this protein with ω >> 1 (Table 2). Com-
parison with the human sequence from Swiss-Prot
(Q99643) and mouse sequence (Q9CZB0) placed 8 of
these sites either in transmembrane or topological
domains across the gene, with the additional positivelyselected residue (position 128) neighboring a metal bind-
ing site at position 127.Positive selection in the Extant Rabbit branch
The SDHC gene again showed evidence of positive selec-
tion, this time in the extant Rabbit lineage with 35.59% of
sites under positive selection (ω = 3.59). 15/51 positively
selected sites were identified as occurring within 10
amino acid positions of the metal binding site 127, also
mentioned in the ancestral Murinae analysis. While there
are extremely high levels of positive selection identified
in the rabbit lineage, no other relevant functional infor-
mation could be gleaned from the databases at this point.
The MUTYH alignment consisted of 21 taxa and
showed evidence of lineage-specific positive selection in
1.4% of sites in the extant Rabbit lineage (ω >> 1). Posi-
tively selected sites were compared to human (Q9UIF7)
and mouse (Q99P21) Swiss-Prot entries, however no
relevant functional information could be extrapolated.
Radical substitutions occurred in all 5 BEB sites in the
extant Rabbit lineage, three of which are at positions
485–487 in the Nudix hydrolase domain.
The MLH1 gene codes for a critical protein involved
with the post-replicative DNA mismatch repair system.
Defects in this gene result in hereditary non-polyposis
colorectal cancer type 2 (HNPCC2) [63]. The alignment
of MLH1 consists of 19 taxa and again positive selection
was detected in the extant rabbit lineage in 0.87% of
sites (ω = 7.53). Positively selected sites were compared
against human Swiss-Prot sequence (P40692) and mouse
Swiss-Prot sequence (Q9JK91). At amino acid position
120, Rabbit has a polar uncharged Serine residue while
all other species tested have a hydrophobic Alanine resi-
due. This positively selected site falls in a region dense
with HNPCC2 variants at positions A111V, T116K,
T117M, Y126N, A128P [63-65]. Positively selected resi-
dues in Rabbit: 209, 478 and 514, each fall within 8
amino acid positions of HNPCC2 variants: V213M,
R474Q and V506A [66]. And position 478 identified as
under positive selection also lies in close proximity to a
colorectal cancer variant R472I [67].
Finally, the BHD gene showed evidence of positive se-
lection in the extant Rabbit lineage. The function of the
BHD gene is still largely unknown, however it is thought
that it may be a tumour suppressor and it may be
involved in colorectal tumorigenesis [68]. The alignment
consisted of 20 taxa and positive selection was detected
in 3.34% of sites (ω = 6.5), again unique to the Rabbit
lineage. BEB significant sites were compared to human
(Q8NFG4) and mouse (Q8QZS3) Swiss-Prot entries to
determine their functional relevance. All 10 of the posi-
tively selected sites in Rabbit occur in a small region
from position 61–83 and border a known human cancer
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Tryptophan results in sporadic colorectal carcinoma.
Positive selection in the Extant Rodent and
Guinea Pig branches
MADH4 is the co-activator and mediator of signal trans-
duction by TGF-beta. Defects in MADH4 result in pan-
creatic, colorectal, juvenile polyposis syndrome, juvenile
intestinal polyposis and primary pulmonary hypertension
[69,70]. The Rat lineage has lineage-specific positive se-
lection in the MADH4 gene where 5.1% of sites are
evolving with ω >> 1 (number of taxa = 16). Positively
selected sites were compared to human (Q13485) and
mouse (P97471) Swiss-Prot entries. The majority of
positively selected residues in this protein are sequential
with 18/24 sites under positive selection in the rat
lineage within 10 amino acid positions of the natural
human variant 493. When position 493 is mutated from
Aspartate to Histidine pancreatic carcinoma is induced
[71].
NF1 is thought to be a regulator of RAS activity [72].
Defects in NF1 can cause colorectal carcinoma and
breast cancer [70]. The NF1 dataset consists of 17 taxa.
Lineage-specific positive selection was identified in 0.92%
of sites in Rat (ω >> 1) and 0.12% of sites in guinea pig
(ω >> 1). BEB significant sites were compared to
human (P21359) and mouse (Q04690) Swiss-Prot
sequences, however there was no functionally relevant
information available.
TSC1 also shows evidence of positive selection in
the extant guinea pig lineage where 1.2% of the sites have
ω >> 1. As before, the positively selected sites were
compared against human Swiss-Prot sequence (Q92574)
and mouse Swiss-Prot sequence (Q9EP53) however there
was insufficient information to extrapolate potential func-
tional impacts of these sites.
Results of site-specific selective pressure analyses
The site-specific results may be beneficial to those work-
ing on rational mutagenesis and/or the identification of
functionally important regions in these colon cancer
associated genes and so these results have been summar-
ized. We have identified five genes that have signatures
of site-specific positive selection, namely: CDH1,
MUTYH, PMS1, PMS2 and TP53, representing ~23% of
the dataset. For each of these five genes, the model of
best fit was the site-heterogeneous model “model 8”, see
Table 2 for summary.
Defects in the CDH1 member of the Cadherin family
are linked to hereditary diffuse gastric cancer [24,28].
The CDH1 alignment contained 15 taxa and site-specific
analyses revealed 0.71% sites evolving under strong posi-
tive selection, ω = 4.54, see Table 2. We compared these
sites to the human Swiss-Prot entry (P12830) to obtainrelevant functional information, see Figure 2(b). The vast
majority of positively selected sites (12 sites) in the pro-
tein are within the extracellular topological domain
(positions 155–709). Many of these positively selected
sites are in close proximity to natural cancer variants.
For example, position 421 is under position selection
and resides within a region (418–423) known to be miss-
ing in gastric carcinoma samples [73]. Positions 457,
465, and 467 are under positive selection and map in
close proximity to natural variant E463Q found in gas-
tric carcinoma samples [49]. Position 700 resides within
the metalloproteinase cleavage site (700–701) of CDH1.
Position 735 is in close proximity to a gamma-secretase
/PS1 cleavage site (731–732) [74], and position 553 is in
close proximity to a glycosylation site (558), essential for
the posttranslational modification of proteins [75]. In
the CDH1 gene, the majority of species tested (8/15)
have hydrophobic residues (Isoleucine, Valine, Leucine)
at position 553, the glires group (mouse, rat, guinea pig
and rabbit) have small residues (Alanine, Serine, Threo-
nine), but human, gorilla, and dog have large aromatic
residues (Phenylalanine) that could significantly alter the
protein structure and may affect binding at the glycosy-
lation site at position 558.
The MUTYH dataset consisted of 21 taxa and site-
specific analysis identified 18 sites under positive selec-
tion (ω = 2.44), representing 2.8% of the MUTYH protein
(Table 2). A total of 10 unique sites are reported as nat-
ural cancer variants in human (Q9UIF7), see Figure 2(c).
Positively selected sites 406 and 412 are in close proxim-
ity to natural cancer variants at positions 402 and 411.
Positively selected sites 521, 528 and 538 also map in
close proximity to natural variants, 526 and 531 respect-
ively. Also of note are the replacement substitutions
observed at Swiss-Prot positions 406 and 412, these are
radical with potential effects on protein structure. At
position 406 there is a large aromatic Trytophan in Pri-
mates, and a hydrophobic Leucine and Valine present in
the Glires. At position 412 there is an hydrophobic Leu-
cine in Primates and a positively charged Histidine in
the Glires.
PMS1 (postmeiotic segregation increased 1) encodes a
DNA mismatch repair protein and this dataset consists
of 20 taxa. Defects in PMS1 are reported to cause heredi-
tary non-polyposis colorectal cancer type 3 (HNPCC3)
[76]. Analysis of PMS1 identified site-specific model of
codon evolution model 8 as best fit, estimating 25 posi-
tively selected sites (6.4% of the alignment) with ω = 1.33
(Table 2). We compared these sites against human
Swiss-Prot sequence P54277. Positively selected site 387
resides in close proximity to position 394 - a natural vari-
ant (M394T) reported in incomplete HNPCC and
HNPCC3 [77]. Due to limited functional data it was un-
feasible to study the remaining 24 sites. However, due to
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selected sites could prove ideal as candidates for muta-
genesis studies in the future.
Mismatch repair endonuclease PMS2 (postmeiotic
segregation increased 2) is a component of the post-
replicative DNA mismatch repair system [78]. Defects in
PMS2 are reported in HNPCC [76]. The PMS2 dataset
contained 21 taxa and site-specific analysis identified
8.9% of sites under positive selection in this PMS2 pro-
tein, ω = 1.29 (Table 2). Functional relevance of these
sites was determined by comparison to Human Swiss-
Prot sequence (P54278). The vast majority of sites (32)
reside within the 430–645 region of the alignment. This
region of the alignment is highly variable and could not
be not improved manually. Functional characterization
for this region is also lacking and therefore we could not
assess functional relevance. Outside this region, two
positively selected sites, 402 and 406 (PP = 0.632 and
0.728 respectively) flank a phosphoserine modification
site (403) [79]. Both substitutions are radical and could
affect the function at position 403.
TP53 (cellular tumor antigen p53) acts as a tumor
suppressor by inducing apoptosis or arresting growth
depending on the physiological circumstances and cell
type [80]. The TP53 protein (P04637) is 393 residues in
length with 343 of these sites reported as natural var-
iants that cause/lead to cancer including but not lim-
ited to colorectal and gastric cancers [41,81,82]. In our
analysis of TP53 we have 16 taxa. Mutations in this
gene radically affect function and therefore we would
expect to find evidence of strong purifying selection
across sites and lineages. However, results indicate that
site specific positive selection is at work with 13 sites
under positive selection, ω = 1.97. See Figure 2(d) and
Table 2 for detailed analyses. On inspection of these 14
sites, we determine that 11 are located within the first
region of the protein (positions 1–83), a region respon-
sible for interaction with the methyltransferase
HRMT1L2 and the recruiting of promoters to the TP53
gene [83]. We identified a cluster of positively selected
sites, namely positions 46 and 47, along with an add-
itional 7 sites within ten residues 39, 52, 53, 54, 55, 56,
and 59 (see Additional file 4). Mutation of position 46
can abolish phosphorylation by HIPK2 and acetylation
of K-382 by CREBBP [84]. Region 66–110 of TP53 is
involved in interaction with WWOX protein and we
have identified two sites (Swiss-Prot positions: 72 and
81), under positive selection within this region. Positively
selected position 129, is located within a region reported
to interact with HIPK1 (100–370) and AXIN1 (116–
292), and in addition is also located within a region
(positions 113–236) that is required for interaction with
FBX042. Positively selected residue 355 is located within
the CARM1 interaction region (300–393), the HIPK2interacting region (319–360), and the oligomerization
region (325–356).
Conclusion
The results we have presented are indicative of selective
pressures acting in a lineage-specific manner. The posi-
tively selected sites we have identified in this study fre-
quently reside in regions of functional importance, such
as glycosylation sites, protease cleavage sites, and sites
known to interact with proteins involved in DNA dam-
age repair pathways. Also of note, positively selected
residues are frequently located at, or in close proximity
to, known cancer associated sites although the statistical
significance of these coincidences cannot be concluded
with such a small sample sizes. Larger sample sizes and
more complete functional information will be hugely
beneficial in resolving whether these positively selected
residues are most likely positioned to or at variants asso-
ciated with cancer.
In using the mouse as a model organism for colon
cancer, we are making an assumption that the orthologs
in both species are functioning in precisely the same
way despite ~ 180 MY of independent evolution. We
found no evidence of functional divergence in the extant
human and mouse lineages for the genes analyzed. How-
ever, upon testing the lineages leading from the MRCA
of mouse and human, i.e. Euarchontoglires, positive se-
lection has occurred on certain ancestral branches and
in specific extant lineages. In the ancestral lineages of
primates, rodents and glires there is evidence of positive
selection in 6 of the 22 genes tested (this includes the
VHL result but as from Table 2 it is clear that this is a
weak result). In total, considering all lineages analyzed
including extant lineages, we have detected lineage-
specific positive selection in 64% of the genes analyzed
(i.e. 14/22 genes). Studies on the levels of polymorphism
observed in Drosophila species indicate that positive se-
lection is pervasive in this species with positive selection
present in ~25% of the genes [85]. Previous studies on
the levels of positive selection in primates compared to
rodents and in the Hominidae reveal much lower levels
of positive selection in the range of 5-9% of genes in the
genome [7,8]. If these previous analyses were to act as a
measurement of expectation then we should have identi-
fied only 1 gene under positive selection in this dataset
that is comprised of mammals for the most part (taking
the Drosophila data as the upper bound we would ex-
pect in the region of 6 genes with evidence of positive
selection).
On grouping the cancer associated genes according to
their involvement in functional pathways we determined
that the MMR DNA damage response pathway has evi-
dence of positive selection in 3 components of the path-
way – 2 of which are site-specific and one of which is
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specific selective pressure in this clade for this process.
The site-specific analyses identified a total of 5 genes that
are positively selected: CDH1, MUTYH, PMS1, PMS2
and TP53. These results are important for contributing
to our understanding of fundamental functions of these
proteins and have provided potential targets for rational
mutagenesis.
Overall, these results indicate that the function of cer-
tain proteins associated with colon cancer display dis-
tinct lineage-specific patterns of substitution indicative
of positive selection in the ancestral human and mouse
lineages. There are a number of selective pressures on
any given protein that can contribute to patterns of sub-
stitution that are “falsely” indicative of positive selection.
The necessity to continue to interact with protein part-
ners may be a strong driving force in the evolution of
the proteins in this study as many form functional com-
plexes with one another or other proteins [86]. Compen-
satory mutations may also contribute to elevated levels
of ω [87]. The effective population size (Ne) of the spe-
cies tested vary enormously, with estimations for mod-
ern human populations in the range of Ne= 7,500 to
3,100 [88], while estimations for modern mouse popula-
tions range from Ne= 58,000 to 25,000 [89] and this
large difference in Ne may also contribute to detection
of false positives. We have also detected weak evidence
for ongoing selective pressure in the human genome on
the STK11 and CDH1, but these signals of selection may
be artifacts of the very small effective population size of
modern humans. Smaller Ne values are associated with
increased fixation of slightly deleterious substitutions
and subsequent elevated ω values [90]. Such slightly
deleterious mutations in turn can lead to additional
compensatory substitutions that become fixed. Teasing
apart substitutions that have become fixed due to posi-
tive selection from slightly deleterious substitutions fixed
due to small Ne [91] will aid in a more complete under-
standing of protein evolution in the future.Additional files
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